Robert John Motzer
Brigham and Women's Hospital
3 papers in the Anchorcite directory, published between 2007 and 2018, cited 16,492 times in total.
ORCID profileResearch topics
- Renal cell carcinoma treatment · 3 papers
- Cancer Immunotherapy and Biomarkers · 2 papers
- Ferroptosis and cancer prognosis · 2 papers
- Hepatocellular Carcinoma Treatment and Prognosis · 1 paper
- Bladder and Urothelial Cancer Treatments · 1 paper
Frequent co-authors
- Bernard J. Escudier · 2 papers
- David F. McDermott · 2 papers
- Saby George · 2 papers
- Hans J. Hammers · 2 papers
- Elizabeth R. Plimack · 2 papers
- Daniel Castellano · 2 papers
- Toni K. Choueiri · 2 papers
- Howard Gurney · 2 papers
Papers
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine · 2007 · 5,822 citations
BACKGROUND: Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted. METHODS: We enrolled 750 patients with previously untreated,…
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2018 · 4,757 citations
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in…
Metadata from OpenAlex (CC0).